Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316886 | 1.00 | LMNA (0.45) | LMNACES2ALDH1A1ALOX15 | |
| SCHEMBL25239151 | 0.82 | — | — | |
| SCHEMBL455930 | 0.80 | ALDH1A1 (0.36) | ALDH1A1ALOX15 | |
| SCHEMBL3549870 | 0.80 | ALDH1A1 (0.36) | ALDH1A1ALOX15 | |
| SCHEMBL9926598 | 0.79 | NR1H2 (0.30) | — | |
| SCHEMBL23319668 | 0.77 | CES2 (0.35) | LMNACES2ALDH1A1 | |
| SCHEMBL2827222 | 0.74 | CES2 (0.33) | LMNACES2ALDH1A1ALOX15 | |
| SCHEMBL91212 | 0.73 | ALDH1A1 (0.31) | ALDH1A1ALOX15 | |
| SCHEMBL12390034 | 0.73 | ALDH1A1 (0.31) | ALDH1A1ALOX15 | |
| SCHEMBL3544456 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331690-A1 | THC DERIVATIVES, ORAL DOSAGE FORMS COMPRISING SAME, USES THEREOF FOR TREATING DISEASES AND DISORDERS AND SYNTHESIS THEREOF | EYBNA TECHNOLOGIES LTD. (IL) | 2023-10-19 | — | — | US | claimed |
| EP-4237416-A1 | THC DERIVATIVES, ORAL DOSAGE FORMS COMPRISING SAME, USES THEREOF FOR TREATING DISEASES AND DISORDERS AND SYNTHESIS THEREOF | Bar Ilan University (IL) | 2023-09-06 | — | — | EP | claimed |
| WO-2022091098-A1 | THC DERIVATIVES, ORAL DOSAGE FORMS COMPRISING SAME, USES THEREOF FOR TREATING DISEASES AND DISORDERS AND SYNTHESIS THEREOF | BAR-ILAN UNIVERSITY (IL) | 2022-05-05 | — | — | WO | claimed |
| US-20230331690-A1 | THC DERIVATIVES, ORAL DOSAGE FORMS COMPRISING SAME, USES THEREOF FOR TREATING DISEASES AND DISORDERS AND SYNTHESIS THEREOF | EYBNA TECHNOLOGIES LTD. (IL) | 2023-10-19 | — | — | US | disclosed |
| EP-4237416-A1 | THC DERIVATIVES, ORAL DOSAGE FORMS COMPRISING SAME, USES THEREOF FOR TREATING DISEASES AND DISORDERS AND SYNTHESIS THEREOF | Bar Ilan University (IL) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022091098-A1 | THC DERIVATIVES, ORAL DOSAGE FORMS COMPRISING SAME, USES THEREOF FOR TREATING DISEASES AND DISORDERS AND SYNTHESIS THEREOF | BAR-ILAN UNIVERSITY (IL) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331690-A1 | THC DERIVATIVES, ORAL DOSAGE FORMS COMPRISING SAME, USES THEREOF FOR TREATING DISEASES AND DISORDERS AND SYNTHESIS THEREOF | CNR2, CNR1, UGT1A10 | LMNA 3918/4885CES2 1175/4885ALDH1A1 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.